- Home
- GNPX vs APVO Comparison
GNPX vs APVO Comparison
Compare GNPX & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNPX
- APVO
- Stock Information
- Founded
- GNPX 2009
- APVO 2016
- Country
- GNPX United States
- APVO United States
- Employees
- GNPX N/A
- APVO N/A
- Industry
- GNPX Biotechnology: Pharmaceutical Preparations
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- GNPX Health Care
- APVO Health Care
- Exchange
- GNPX Nasdaq
- APVO Nasdaq
- Market Cap
- GNPX 7.0M
- APVO 4.1M
- IPO Year
- GNPX 2018
- APVO N/A
- Fundamental
- Price
- GNPX $0.29
- APVO $0.36
- Analyst Decision
- GNPX Strong Buy
- APVO Strong Buy
- Analyst Count
- GNPX 1
- APVO 1
- Target Price
- GNPX $10.00
- APVO $296.00
- AVG Volume (30 Days)
- GNPX 2.6M
- APVO 3.6M
- Earning Date
- GNPX 05-16-2025
- APVO 05-20-2025
- Dividend Yield
- GNPX N/A
- APVO N/A
- EPS Growth
- GNPX N/A
- APVO N/A
- EPS
- GNPX N/A
- APVO N/A
- Revenue
- GNPX N/A
- APVO N/A
- Revenue This Year
- GNPX N/A
- APVO N/A
- Revenue Next Year
- GNPX N/A
- APVO N/A
- P/E Ratio
- GNPX N/A
- APVO N/A
- Revenue Growth
- GNPX N/A
- APVO N/A
- 52 Week Low
- GNPX $0.22
- APVO $0.35
- 52 Week High
- GNPX $4.09
- APVO $38.48
- Technical
- Relative Strength Index (RSI)
- GNPX 48.94
- APVO 24.79
- Support Level
- GNPX $0.27
- APVO $0.60
- Resistance Level
- GNPX $0.36
- APVO $0.80
- Average True Range (ATR)
- GNPX 0.03
- APVO 0.12
- MACD
- GNPX 0.01
- APVO 0.04
- Stochastic Oscillator
- GNPX 47.45
- APVO 1.49
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.